Format

Send to

Choose Destination
J Med Chem. 1996 Oct 11;39(21):4299-312.

HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.

Author information

1
DuPont Merck Pharmaceutical Company, E500/3203 Experimental Station, Wilmington, Delaware 19880-0500, USA.

Abstract

A series of N,N'-disubstituted cyclic urea 3-benzamides has been synthesized and evaluated for HIV protease inhibition and antiviral activity. Some of these benzamides have been shown to be potent inhibitors of HIV protease with Ki < 0.050 nM and IC90 < 20 nM for viral replication and, as such, may be useful in the treatment of AIDS. The synthesis and quantitative structure-activity relationship for this benzamide series will be discussed.

PMID:
8863807
DOI:
10.1021/jm9602773
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center